Phase 2 OCD Trial, Recruiting NCT05783817 Sponsor: Carolyn Rodriguez Condition: OCD
Back to Ocd

Phase 2 OCD Trial, Recruiting

NCT05783817
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are at least 18 years old
  • You can speak and read the main language used at the study location
  • You are able to swallow pills
  • You have been diagnosed with OCD (Obsessive-Compulsive Disorder)
  • Your OCD symptoms score at least 16 on a standard OCD severity scale called the YBOCS (confirm with trial site)
  • You have not taken any psychiatric or mood-related medications in the month before joining the study
  • You are comfortable going through a period with no treatment before the study begins
  • You are able to participate in all required study procedures
  • At least one standard first-line OCD treatment has been tried before and did not work for you
  • You agree to follow specific lifestyle rules, including fasting before certain sessions, avoiding certain medications at set times, not joining other clinical trials during this study, and attending all medication, therapy, and study appointments

Who may not be able to join:

  • You are currently pregnant, breastfeeding, or could become pregnant and are not using an effective form of birth control
  • You weigh less than 48 kilograms (about 106 pounds)
  • You have any current health or personal issue that the study doctor feels could interfere with your safe participation in the trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Carolyn Rodriguez, MD, PhD, Stanford University

Phone: 650-723-4095

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Carolyn Rodriguez
Registry
ClinicalTrials.gov
Start date
10 September 2025
Est. completion
1 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Chnage in the severity of OCD symptoms as measured by the Yale-Brown Obsessive Compulsive Scale (YBOCS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov